Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier:
NCT00004015
First received: November 1, 1999
Last updated: July 17, 2012
Last verified: July 2012
  Purpose

RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue.

PURPOSE: This phase I trial is studying the side effects and best dose of boron neutron capture therapy following surgery in treating patients with glioblastoma multiforme removed during surgery.


Condition Intervention Phase
Brain and Central Nervous System Tumors
Drug: sodium borocaptate
Procedure: adjuvant therapy
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Postoperative Treatment of Glioblastoma With BNCT at the Petten Irradiation Facility

Resource links provided by NLM:


Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Acute toxicity as measured by NCIC-Common Toxicity Criteria up to 30 days after the first BSH administration [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Late toxicity as measured by RTOC and EORTC late radiation morbidity scale from 90 days after completion of irradiation treatment until death [ Designated as safety issue: Yes ]
  • Overall survival as measured by Logrank until death [ Designated as safety issue: No ]

Estimated Enrollment: 36
Study Start Date: June 2002
Primary Completion Date: July 2003 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Determine systemic and local toxicity of borocaptate sodium with boron neutron capture therapy (BNCT) following craniotomy with gross total resection in patients with glioblastoma multiforme.
  • Determine the qualitative and quantitative dose-limiting toxicity and maximum tolerated dose of this regimen in these patients.
  • Determine the maximum tolerated radiation dose of BNCT in cranial localization to healthy tissues in these patients under defined conditions.

OUTLINE: This is a dose escalation, multicenter study.

Within 6 weeks of surgery, patients receive borocaptate sodium followed 12-18 hours later by neutron irradiation. Treatment repeats daily for 4 days.

Cohorts of 3-9 patients receive escalating doses of neutron irradiation. The maximum tolerated dose is defined as the dose preceding that at which 3 or more patients experience dose limiting toxicity.

Patients are followed weekly for 4 weeks, monthly for 2 months, every 6 weeks for 15 months and then every 3 months thereafter.

PROJECTED ACCRUAL: Approximately 30-36 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically proven glioblastoma multiforme for which conventional radiotherapy would be of little or no benefit
  • Gross total resection of tumor confirmed by postoperative MRI performed within 48 hours of surgery
  • Evaluable preoperative and postoperative MRI films with and without contrast must be available
  • No prior brain malignancy
  • No prior craniotomy except for glioblastoma

PATIENT CHARACTERISTICS:

Age:

  • 50 and over

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Bilirubin, SGOT, SGPT, and alkaline phosphatase no greater than 2.5 times normal unless caused by reversible reaction to antiseizure medication

Renal:

  • Blood urea nitrogen and creatinine no greater than 2.5 times upper limit of normal

Cardiovascular:

  • No severe heart disease (e.g., congestive heart failure, angina pectoris)

Pulmonary:

  • No severe dyspnea at time of diagnosis
  • No severe obstructive or restrictive lung disease

Other:

  • No other concurrent malignant tumor
  • No severe gastrointestinal disease or active peptic ulcer disease
  • No uncontrolled endocrine disease
  • No serious mental disease, organic brain disease (e.g., preexisting epilepsy or serious aphasia), or legally incapacitated patients

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior biologic therapy for glioblastoma multiforme
  • No concurrent biologic therapy

Chemotherapy:

  • No prior chemotherapy for glioblastoma multiforme
  • No concurrent chemotherapy

Endocrine therapy:

  • No prior endocrine therapy for glioblastoma multiforme except corticosteroids
  • No concurrent endocrine therapy

Radiotherapy:

  • See Disease Characteristics
  • No prior radiotherapy for glioblastoma multiforme
  • No prior radiotherapy to head and neck
  • No other concurrent radiotherapy

Surgery:

  • See Disease Characteristics
  • Prior stereotactic biopsy allowed for glioblastoma multiforme
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004015

Locations
Austria
Karl-Franzens-University Graz
Graz, Austria, A-8010
Canada, Ontario
Toronto Sunnybrook Regional Cancer Centre at Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
France
Hopital Pasteur
Nice, France, 06002
Germany
Universitaetsklinikum Essen
Essen, Germany, D-45122
Klinikum der Universitaet Muenchen - Grosshadern Campus
Munich, Germany, D-81377
Italy
Ospedale Santa Chiara Pisa
Pisa, Italy, 56100
Netherlands
Vrije Universiteit Medisch Centrum
Amsterdam, Netherlands, 1007 MB
EC Joint Research Centre - Institute for Energy
Petten, Netherlands, NL-1755 ZG
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Investigators
Study Chair: Wolfgang Sauerwein, MD, PhD Universitaetsklinikum Essen
  More Information

Additional Information:
Publications:
Gabel D, Touw D, Stecher-Rasmussen F, et al.: Quality control of Na2B12H11SH, a drug boron neutron capture therapy in EORTC trial 11961. [Abstract] Ann Oncol 9(suppl 2): 129, 1998.
Hideghety W, Sauerwein W, DeVries M, et al.: Post-operative treatment of glioblastoma with boron neutron capture therapy at the European High Flux Reactor Petten (EORTC protocol 11961). [Abstract] Ann Oncol 9(suppl 2): 129, 1998.
Sauerwein W, Hideghety K, De Vries M, et al.: Boron neutron capture therapy (BNCT) for the treatment of glioblastoma (EORTC protocol 11961). [Abstract] Radiother Oncol 48(suppl 1): s157, 1998.
Sauerwein W, Hideghety K, De Vries M, et al.: Conducting phase I clinical trial in binary treatment modality: methodical questions for the evaluation of boron neutron capture therapy. [Abstract] Ann Oncol 9(suppl 2): 129, 1998.
Haselsberger K, Pendl G, Sauerwein W, et al.: BNCT for glioblastoma in Europe: design of the EORTC protocol 11961 and clinical course of the first patient. [Abstract] J Neurooncol 39 (2): A-P155, 147, 1998.

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier: NCT00004015     History of Changes
Other Study ID Numbers: EORTC-11961, EORTC-11961
Study First Received: November 1, 1999
Last Updated: July 17, 2012
Health Authority: United States: Federal Government

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
adult glioblastoma
adult giant cell glioblastoma
adult gliosarcoma

Additional relevant MeSH terms:
Glioblastoma
Nervous System Neoplasms
Central Nervous System Neoplasms
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases

ClinicalTrials.gov processed this record on July 29, 2014